LCD L39614: MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma — WPS
Policy LCD-L39614 · Oncology
Covers molecular biomarker testing for skin cancer risk stratification.
Code intelligence
0315U reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code 0315U.
Elevated code risk
Signal breakdown
6 shown · 6 total in platform
Risk: Elevated
0
Critical
0%
6
High
100%
0
Routine
0%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
High
LCD L36021: MolDX: Molecular Diagnostic Tests (MDT) — CGS
Policy LCD-L36021 · Clinical Laboratory
New MolDX policy effective in 2025 may alter billing processes.
LCD L36256: MolDX: Molecular Diagnostic Tests (MDT) — Noridian
Policy LCD-L36256 · Clinical Laboratory
New molecular diagnostics policy may impact billing processes.
LCD L39594: MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma — Noridian
Policy LCD-L39594 · Dermatology
New LCD requires billing team review.
LCD L35160: MolDX: Molecular Diagnostic Tests (MDT) — Noridian
Policy LCD-L35160 · Clinical Laboratory
New MolDX guidelines may alter MDT billing processes.
LCD L39589: MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma — Noridian
Policy LCD-L39589 · Dermatology
Update billing practices for cutaneous SCC biomarker testing.
Audit documentation
Building an audit file that includes 0315U?
The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Oncology audit pack — $349One-time purchase · not a subscription